Open Study Assessing the Feasibility of Minocycline in Patients With Unipolar Depression
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
A single center, open label study assessing the feasibility, safety and therapeutic effect of
Minocycline in adult patients with diagnosis of unipolar depression. Up to 30 patients
diagnosed with unipolar depression that are in a current depressive episode. The patients
will be of all racial, ethnic and gender categories, ranging from 18 to 68 years of age, and
have HDRS-21≥20. All subjects will continue to take their treatment with antidepressant
medications for the duration of the study. All subjects are prescribed minocycline 200 mg/day
orally (2X100 mg) for the first 3 days. than, all subjects are prescribed minocycline 400
mg/day orally (2X200 mg) from day 4 until termination visit (day 35). The primary objective
of this study is to assess the therapeutic effect of Minocycline in unipolar depression.
The secondary objectives of this study are to assess the therapeutic effect, the feasibility
and safety of Minocycline in unipolar depression.